查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1786464

全球藥物傳輸設備市場

Drug and Gene Delivery Devices
出版日期: | 出版商: Global Industry Analysts, Inc. | 英文 278 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

簡介目錄

到 2030 年，全球藥物傳輸設備市場規模將達到 22 億美元

全球給藥裝置市場規模預計在2024年為14億美元，到2030年將達到22億美元，在2024-2030年的分析期間內，複合年成長率為7.5%。口服給藥是本報告分析的細分市場之一，預計其複合年成長率為7.0%，到分析期結束時將達到5.103億美元。吸入給藥細分市場在分析期間的複合年成長率預計為8.9%。

美國市場規模估計為 3.861 億美元，中國市場預計複合年成長率為 11.6%

美國藥物輸送裝置市場規模預計2024年達到3.861億美元。作為世界第二大經濟體，中國市場規模預計到2030年將達到4.59億美元，在2024-2030年的分析期間內，複合年成長率為11.6%。其他值得關注的區域市場包括日本和加拿大，預計在分析期間內，這兩個市場的複合年成長率分別為3.8%和7.2%。在歐洲，預計德國市場的複合年成長率為5.0%。

全球藥物輸送設備市場－主要趨勢與促進因素摘要

藥物輸送裝置方面有哪些突破性創新？

在生物技術、奈米醫學和先進材料科學領域尖端創新的推動下，藥物傳輸裝置市場正在迅速轉型。這些裝置不再只是治療的載體，而是日益複雜的平台，能夠增強藥物和遺傳物質的特異性、穩定性和生物有效性。 CRISPR-Cas9 和RNA干擾(RNAi) 等技術的蓬勃發展，要求輸送系統能夠精準標靶化受影響的細胞，同時最大限度地減少脫靶效應。脂質奈米顆粒、病毒載體和電穿孔技術等新型傳遞機制應運而生，為這些精準治療提供支援。此外，基於聚合物的傳輸載體和微針陣列也正在積極開發，以克服生物屏障並改善全身吸收，特別適用於需要進入細胞內的基因療法。這些進展使得先前因輸送限制而無法實現的療法成為可能。

為什麼個人化醫療會推動對新交付平台的需求？

個人化醫療和精準醫療的轉變正在重新定義治療遞送需求，使得客製化藥物遞送裝置的開發至關重要。根據個體基因特徵客製化治療方案需要能夠適應各種分子量、溶解度和組織標靶的遞送系統。隨著基因組定序速度的加速和便利性提升，市場對患者個人化治療的需求日益成長，尤其是在腫瘤學、罕見疾病和慢性病領域。這推動了對靈活、模組化且可快速配置的遞送系統的需求。此外，將小分子與基因有效載荷結合的聯合治療的興起，使得雙重多模態遞送能力成為必要。監管機構也不斷改進相關框架，以應對個人化治療的複雜性，從而加速下一代遞送裝置的核准和上市。

非侵入性和有針對性的交付方法將在市場發展中發揮什麼作用？

病患偏好和醫療服務提供者優先順序的不斷變化，促使人們對非侵入性和特異性給藥技術投入巨額資金。口服、鼻腔、肺部和經皮給藥系統由於患者依從性和給藥便捷性，比注射劑更受歡迎。尤其是吸入式基因治療領域發展勢頭強勁，為囊腫纖維化和肺動脈高壓等呼吸系統疾病提供了切實可行的替代方案。配備感測器、微處理器和連接功能的智慧給藥設備也促進了這一轉變，能夠即時監控治療的實施和療效。這些設備正成為數位健康生態系統的重要組成部分，尤其是在居家照護環境中。此外，透過抗體藥物複合體(ADC)、適體系統和磁場引導奈米粒子實現的特異性靶向作用，可以降低全身毒性並增強治療效果，為更安全、更有效的治療鋪平道路。

藥物輸送裝置市場的成長受到多種因素的推動…

奈米和微米工程技術的快速進步正在徹底改變遞送平台的設計和性能，實現前所未有的控釋和靶向遞送。慢性病和遺傳疾病的增多，加上基因治療和核酸藥物臨床試驗的增加，正在推動市場對客製化遞送系統的需求。從最終用途的角度來看，製藥公司正在大力投資下一代遞送系統，以區分生物製藥組合併透過新配方延長專利期。學術研究機構和委外研發機構(CRO) 也透過合作開發專案為擴大產品線做出貢獻。在消費者方面，人們越來越偏好微創或自我管理的治療方法，尤其是在老年人口和兒科護理中。同時，醫療保健提供者正在尋求與數據生態系統整合的遞送解決方案，以便監測患者和最佳化治療。這些趨勢結合，正在全球創造一個強勁而充滿活力的市場格局。

部分

給藥途徑（口服、吸入、經皮、注射、眼部、鼻部、局部）；載體（病毒、非病毒）

受訪公司範例

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company（BD）
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

人工智慧整合

我們正在利用有效的專家內容和人工智慧工具來改變市場和競爭情報。

Global 特定產業產業SLM 的典型規範，而是建立了一個從世界各地專家收集的內容庫，包括影片錄影、部落格、搜尋引擎研究以及大量的公司、產品/服務和市場數據。

關稅影響係數

全球產業分析師根據公司總部所在國家、製造地和進出口（成品和原始設備製造商）情況預測其競爭地位的變化。這種複雜而多面的市場動態預計將以多種方式影響競爭對手，包括銷貨成本(COGS) 上升、盈利下降、供應鏈重組以及其他微觀和宏觀市場動態。

目錄

第1章調查方法

第2章執行摘要

  • 市場概覽
  • 主要企業
  • 市場趨勢和促進因素
  • 全球市場展望

第3章市場分析

  • 美國
  • 加拿大
  • 日本
  • 中國
  • 歐洲
  • 法國
  • 德國
  • 義大利
  • 英國
  • 西班牙
  • 俄羅斯
  • 其他歐洲國家
  • 亞太地區
  • 澳洲
  • 印度
  • 韓國
  • 其他亞太地區
  • 拉丁美洲
  • 阿根廷
  • 巴西
  • 墨西哥
  • 其他拉丁美洲
  • 中東
  • 伊朗
  • 以色列
  • 沙烏地阿拉伯
  • 阿拉伯聯合大公國
  • 其他中東地區
  • 非洲

第4章 比賽

簡介目錄
Product Code: MCP30606

Global Drug and Gene Delivery Devices Market to Reach US$2.2 Billion by 2030

The global market for Drug and Gene Delivery Devices estimated at US$1.4 Billion in the year 2024, is expected to reach US$2.2 Billion by 2030, growing at a CAGR of 7.5% over the analysis period 2024-2030. Oral, one of the segments analyzed in the report, is expected to record a 7.0% CAGR and reach US$510.3 Million by the end of the analysis period. Growth in the Inhalation segment is estimated at 8.9% CAGR over the analysis period.

The U.S. Market is Estimated at US$386.1 Million While China is Forecast to Grow at 11.6% CAGR

The Drug and Gene Delivery Devices market in the U.S. is estimated at US$386.1 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$459.0 Million by the year 2030 trailing a CAGR of 11.6% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 3.8% and 7.2% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.0% CAGR.

Global Drug and Gene Delivery Devices Market - Key Trends & Drivers Summarized

How Are Breakthrough Innovations Reshaping Drug and Gene Delivery Devices?

The drug and gene delivery devices market has undergone rapid transformation, driven by cutting-edge innovations in biotechnology, nanomedicine, and advanced material sciences. These devices are no longer just conduits for therapeutic agents but are becoming increasingly sophisticated platforms that enhance specificity, stability, and bioavailability of drugs and genetic material. Techniques like CRISPR-Cas9 and RNA interference (RNAi) have surged in prominence, requiring delivery systems that can precisely target affected cells while minimizing off-target effects. Novel delivery mechanisms such as lipid nanoparticles, viral vectors, and electroporation technologies have emerged to support these precision therapies. Additionally, polymer-based delivery vehicles and microneedle arrays are being actively developed to overcome biological barriers and improve systemic absorption, especially for gene therapies requiring intracellular access. These developments are enabling therapies that were previously not viable due to delivery limitations.

Why Is Personalized Medicine Fueling the Demand for Novel Delivery Platforms?

The transition toward personalized and precision medicine has redefined therapeutic delivery requirements, making the development of customized drug and gene delivery devices essential. Tailoring treatments based on individual genetic profiles demands delivery systems that can adapt to varying molecular weights, solubility characteristics, and tissue targets. As genomic sequencing becomes faster and more accessible, the market is experiencing increased demand for patient-specific therapies, particularly in oncology, rare diseases, and chronic conditions. This has led to a growing need for flexible and modular delivery systems that can be rapidly configured. Furthermore, the rise of combination therapies-blending small molecules with genetic payloads-necessitates dual or multi-modal delivery capabilities. Regulatory agencies are also evolving their frameworks to accommodate the complex nature of personalized therapeutics, which is accelerating approvals and market entry of next-generation delivery devices.

What Role Do Non-Invasive and Targeted Delivery Methods Play in Market Evolution?

Shifting patient preferences and healthcare provider priorities have spurred significant investment in non-invasive and site-specific delivery technologies. Oral, nasal, pulmonary, and transdermal routes are gaining popularity over injectable formats due to better patient compliance and ease of administration. In particular, the inhalable gene therapy segment is gaining momentum, offering a practical alternative for respiratory diseases such as cystic fibrosis and pulmonary hypertension. Smart delivery devices equipped with sensors, microprocessors, and connectivity features are also contributing to this shift, enabling real-time monitoring of therapeutic administration and outcomes. These devices are becoming integral to digital health ecosystems, especially in home-care settings. Moreover, site-specific targeting-achieved through antibody-drug conjugates (ADCs), aptamer systems, and magnetic field-guided nanoparticles-is reducing systemic toxicity and enhancing therapeutic efficacy, paving the way for safer, more efficient treatments.

The Growth in the Drug and Gene Delivery Devices Market Is Driven by Several Factors…

Rapid technological advancements in nano- and micro-scale engineering have revolutionized the design and performance of delivery platforms, enabling controlled release and targeted delivery like never before. The rise in chronic and genetic diseases, alongside increasing clinical trials for gene therapies and nucleic acid-based drugs, is propelling market demand for compatible delivery systems. From an end-use perspective, pharmaceutical companies are investing heavily in next-gen delivery systems to differentiate their biologic portfolios and extend patent life through novel formulations. Academic research institutions and contract research organizations (CROs) are also contributing to pipeline expansion through collaborative development programs. On the consumer side, there is a growing preference for minimally invasive or self-administrable treatment modalities, especially in the aging population and pediatric groups. In parallel, healthcare providers are seeking delivery solutions that integrate with data ecosystems for patient monitoring and treatment optimization. Together, these trends are forging a robust and dynamic market landscape for drug and gene delivery devices globally.

SCOPE OF STUDY:

The report analyzes the Drug and Gene Delivery Devices market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Administration Route (Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal, Topical); Vector (Viral, Non-viral)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca plc
  • Bayer AG
  • Becton, Dickinson and Company (BD)
  • Biogen Inc.
  • Bluebird Bio, Inc.
  • Bristol-Myers Squibb Company
  • F. Hoffmann-La Roche Ltd
  • Genentech, Inc.
  • Halozyme Therapeutics, Inc.
  • Johnson & Johnson Services, Inc.
  • Kite Pharma, Inc.
  • Merck & Co., Inc.
  • Moderna, Inc.
  • Novartis AG
  • Oxford BioMedica plc
  • Pfizer Inc.
  • Sarepta Therapeutics, Inc.
  • Shanghai Sunway Biotech Co., Ltd.

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Tariff Impact on Global Supply Chain Patterns
    • Drug and Gene Delivery Devices - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Chronic and Genetic Disorders Accelerates Demand for Advanced Drug and Gene Delivery Devices
    • Breakthroughs in mRNA Technology Strengthen the Business Case for Next-Generation Delivery Platforms
    • Growing Pipeline of Biologics and Cell & Gene Therapies Expands Addressable Market Opportunity for Novel Delivery Systems
    • Emergence of Personalized Medicine Spurs Innovation in Targeted and Localized Delivery Technologies
    • Favorable Regulatory Pathways and Fast-Track Approvals Propel Growth in Gene Therapy Delivery Solutions
    • Advancements in Nanocarriers and Lipid-Based Delivery Systems Drive Adoption in Precision Medicine
    • Increased Focus on Blood-Brain Barrier Penetration Throws the Spotlight on Intranasal and Intrathecal Delivery Methods
    • Rising Investment in Non-Viral Vectors Enhances Market Potential for Safer and Scalable Gene Delivery Approaches
    • Minimally Invasive Delivery Techniques Generate Demand for Needle-Free and Implantable Drug Delivery Devices
    • Shift Toward At-Home Treatment Models Sustains Growth of Wearable and Self-Administered Drug Delivery Systems
    • Strategic Collaborations Between Pharma and MedTech Firms Propel Innovation in Hybrid Drug-Device Products
    • Challenges in Payload Stability and Targeted Delivery Create Opportunities for Formulation-Device Integration
    • Growing Global Access to Advanced Therapies Drives Expansion of Drug and Gene Delivery Infrastructure in Emerging Markets
    • Evolving Regulatory Standards for Combination Products Create Both Hurdles and Opportunities in Product Commercialization
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Drug and Gene Delivery Devices Market Analysis of Annual Sales in US$ Thousand for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Drug and Gene Delivery Devices by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Inhalation by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Inhalation by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Transdermal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Transdermal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Injectable by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Injectable by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Ocular by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Ocular by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Nasal by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Nasal by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Topical by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Topical by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Non-viral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Non-viral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • JAPAN
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • CHINA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • EUROPE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Drug and Gene Delivery Devices by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • FRANCE
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • GERMANY
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • INDIA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Drug and Gene Delivery Devices by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Drug and Gene Delivery Devices by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030
  • AFRICA
    • Drug and Gene Delivery Devices Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Drug and Gene Delivery Devices by Administration Route - Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Administration Route - Percentage Breakdown of Value Sales for Oral, Inhalation, Transdermal, Injectable, Ocular, Nasal and Topical for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Drug and Gene Delivery Devices by Vector - Viral and Non-viral - Independent Analysis of Annual Sales in US$ Thousand for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Drug and Gene Delivery Devices by Vector - Viral and Non-viral Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Drug and Gene Delivery Devices by Vector - Percentage Breakdown of Value Sales for Viral and Non-viral for the Years 2015, 2025 & 2030

IV. COMPETITION